COMMETS- Combination MCI Metabolic Syndrome

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome

In brief

The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with MetS (metabolic syndrome) and MCI (Mild Cognitive Impairment), who are enriched for cerebrovascular disease and at high dementia risk. The study will focus on cognitive and biological outcomes, allowing identification of relevant mechanisms.

Key facts

Study ID
NCT06072963
Run by
Rutgers, The State University of New Jersey
People needed
80
Starts
2024-01-30
Expected to finish
2028-12-01
Last updated by the study team
2026-07-27

Who can join

Age: 60 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.